CanSinoBIO’s Convidecia Air™ Approved for Emergency Use in Morocco

Tianjin, November 10, 2022 - CanSino Biologics Inc. (“CanSinoBIO”) (SSE: 688185, HKEX: 06185) today announced that its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation (trade name: Convidecia Air™) has been approved for emergency use by the Ministre de la Sante  et de la Protection Sociale (Maroc), Morocco’s Ministry of Health and Social Protection, representing the first overseas approval of Convidecia Air™.

Convidecia Air™, utilizing Aerogen’s proprietary aerosol drug delivery technology, has so far been approved for emergency use in China and Morocco. It is the world’s first approved inhaled COVID-19 vaccine, based on the same adenovirus vector technological platform of CanSinoBIO’s Convidecia™ administered via intramuscular injection.

Peer-reviewed research1 shows that Convidecia Air™ is safe to use with only one-fifth of the dosage of the intramuscular version of CanSinoBIO’s COVID-19 vaccine. By using Convidecia Air™ as a heterologous booster, it generated much stronger immune responses than those induced by a homologous inactivated vaccine booster2. The inhaled treatment can achieve triple protection as it triggers a mucosal immune response in addition to humoral and cellular immunity observed in people who were vaccinated with the intramuscular version.

Currently, Convidecia Air™ has been rolled out in China, including Shanghai, Tianjin, and Jiangsu province, to help strengthen protection for the Chinese population against COVID-19 and its variants with a more efficient delivery method which is needle-free, painless and non-invasive.